Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x10^9/L at PAC initiation: Interim results from the MY-PAC Study

Publication

EHA •
15 June, 2025 •
•

Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database

Aaron T Gerds, Lucia Masarova, Nicole M Engel-Nitz, Michael Marrone, Jefferey McPheeters, Abiola Oladapo, Purvi Suthar, Michael Vredenburg , Yong Zhu, Lindsay AM Rein

Available materials

Poster

Publication

EHA •
15 June, 2025 •
•

Real-world effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Raajit Rampal, Samantha Eiffert, Michael Marrone, Lisa Morere, Abiola Oladapo, Anubhav Sharma, Purvi Suthar, Anupama Vasudevan, Michael Vredenburg , John Mascarenhas

Available materials

Poster

Symposium

EHA •
14 June, 2025 •
•

Boosting Platelets: Expert Approaches to Adult Immune Thrombocytopenia (ITP)

Monica Carpenedo, María Luisa Lozano, Waleed Ghanima

Available materials

Slides Video

Publication

SOHO •
4 September, 2025 •
•

Hematologic response in patients with myelofibrosis treated with pacritinib in real-word clinical settings

Raajit Rampal, Samantha Eiffert, Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Anupama Vasudevan, Michael Vredenburg , John Mascarehnas

Available materials

Poster

Publication

SOHO •
4 September, 2025 •
•

Cytopenia is associated with real-world disease progression and diminished survival in patients with myelofibrosis: Analysis of a US national administrative claims database

Lindsay AM Rein, Nicole M Engel-Nitz, Michael Marrone, Jeffrey McPheeters, Abiola Oladapo, Purvi Suthar, Michael Vredenburg , Yong Zhu, Aaron T Gerds, Lucia Masarova

Available materials

Poster

Publication

SOHO •
3 September, 2025 •
•

Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib previously treated with ruxolitinib

John Mascarehnas, Samantha Eiffert, Michael Marrone, Lisa Morere, Abiola Oladapo, Anubhav Sharma, Purvi Suthar, Anupama Vasudevan, Michael Vredenburg , Raajit Rampal

Available materials

Poster

Symposium

EULAR •
13 June, 2025 •
•

Putting on your VEXAS goggles: Seeing what’s in plain sight

Sophie Georgin-Lavialle, Thibault Mahevas, Lachelle D. Weeks, Sara Bindoli

Available materials

Slides Video

Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x10^9/L at PAC initiation: Interim results from the MY-PAC Study

Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database

Real-world effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Boosting Platelets: Expert Approaches to Adult Immune Thrombocytopenia (ITP)

Hematologic response in patients with myelofibrosis treated with pacritinib in real-word clinical settings

Cytopenia is associated with real-world disease progression and diminished survival in patients with myelofibrosis: Analysis of a US national administrative claims database

Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib previously treated with ruxolitinib

Putting on your VEXAS goggles: Seeing what’s in plain sight​

Putting on your VEXAS goggles: Seeing what’s in plain sight